PROM1 and acute myeloid leukemia: Recently, Rothfelder et al. reported that 293C3-SDIE, an FC-engineered CD133 monoclonal antibody, induced degranulation and lysis of primary CD133 positive AML cells by natural killer cells in allogeneic and autologous ex vivo settings.